Figure 1.
Figure 1. T cells from DLBCL patients who have received multiple rounds of chemotherapy show loss of CD27 and CD28 expression. Peripheral blood samples from healthy controls, untreated DLBCL patients, and heavily-treated DLBCL patients were examined for the expression of CD27 and CD28 by flow cytometry. (A) Representative flow plots of CD27 and CD28 expression gated on CD3+ cells. (B) Quantification of CD27−CD28− cells from healthy controls (n = 6), untreated DLBCL patients (n = 5), and treated DLBCL patients (n = 12). Horizontal bar shows mean values; vertical “whiskers” show 95% confidence interval. (C) Linear regression showing the correlation between number of total chemotherapy cycles and frequency of CD27−CD28− cells in DLBCL patient samples. Colored symbols and connecting lines indicate paired blood samples taken from DLBCL prior to and following cytotoxic chemotherapy.

T cells from DLBCL patients who have received multiple rounds of chemotherapy show loss of CD27 and CD28 expression. Peripheral blood samples from healthy controls, untreated DLBCL patients, and heavily-treated DLBCL patients were examined for the expression of CD27 and CD28 by flow cytometry. (A) Representative flow plots of CD27 and CD28 expression gated on CD3+ cells. (B) Quantification of CD27−CD28− cells from healthy controls (n = 6), untreated DLBCL patients (n = 5), and treated DLBCL patients (n = 12). Horizontal bar shows mean values; vertical “whiskers” show 95% confidence interval. (C) Linear regression showing the correlation between number of total chemotherapy cycles and frequency of CD27−CD28− cells in DLBCL patient samples. Colored symbols and connecting lines indicate paired blood samples taken from DLBCL prior to and following cytotoxic chemotherapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal